4′-trans-Hydroxy Cilostazol (CAS 87153-04-6)

ZDHHC3 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of ZDHHC3, a protein encoded by the ZDHHC3 gene. ZDHHC3, also known as zinc finger DHHC-type palmitoyltransferase 3, is an enzyme that plays a critical role in the process of protein palmitoylation. Palmitoylation is a post-translational modification where a palmitoyl group (a type of fatty acid) is covalently attached to cysteine residues on proteins, which influences their membrane association, trafficking, stability, and function. ZDHHC3 is one of several DHHC-type palmitoyltransferases, characterized by the presence of a DHHC (Asp-His-His-Cys) cysteine-rich domain, which is essential for its enzymatic activity. Structurally, ZDHHC3 inhibitors can vary widely, including small molecules, peptides, or other biomolecules engineered to interact specifically with the catalytic site or regulatory domains of the ZDHHC3 protein. These inhibitors typically bind to the DHHC domain or other critical regions, blocking the enzyme′s ability to transfer palmitoyl groups to substrate proteins. By inhibiting ZDHHC3, these compounds can disrupt the palmitoylation process, leading to changes in the localization, stability, and function of target proteins. The study of ZDHHC3 inhibitors is crucial for understanding the regulatory mechanisms of protein palmitoylation and its impact on cellular signaling and membrane dynamics. Research into these inhibitors provides valuable insights into the broader implications of palmitoylation on protein function, including how alterations in this modification can affect cellular processes such as signal transduction, vesicular trafficking, and protein-protein interactions. By exploring the effects of ZDHHC3 inhibition, scientists can gain a deeper understanding of the role of palmitoylation in maintaining cellular homeostasis and the functional organization of the cell.